(RTTNews) – Ascletis Pharma Inc. (ASCLF.PK) introduced that it has submitted advertising authorization application for ritonavir 100 mg movie-coated pill in the Hong Kong Particular Administrative Location of the People’s Republic of China.
Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, stated, “In addition to filing advertising authorization purposes for ritonavir in various nations around the world/locations, we are accelerating the advancement of ASC10 and ASC11, two novel oral drug candidates from COVID-19”.
Prognosis and Cure Protocol for Novel Coronavirus Pneumonia (Demo Model 9) unveiled on March 15, 2022 by the National Wellbeing Fee of the People’s Republic of China contains PF-07321332/ritonavir (Paxlovid) as an antiviral therapy, the business stated.
Ascletis has submitted marketing authorization purposes for ritonavir (100 mg film-coated pill) in 12 European nations around the world (Germany, France, Ireland, the United Kingdom, Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark) as a result of its agent in Europe.
The views and thoughts expressed herein are the views and opinions of the author and do not always reflect those of Nasdaq, Inc.
2010 H-1B Applications and the H-1B Cap
Writing a Job Application Letter Impressively
Essential Mobile Application Development Facts